Visual acuity and central retinal thickness: Fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care

British Journal of Ophthalmology

Volumn 98, Issue 10, 2014, Pages 1333-1337

  Reznicek, Lukas ^a   Muhr, Johanna ^a   Ulbig, Michael ^a   Kampik, Anselm ^a   Mayer, Wolfgang J ^a   Haritoglou, Christos ^a   Neubauer, Aljoscha ^a   Wolf, Armin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DIAGNOSTIC TEST ACCURACY STUDY; DRUG INDICATION; EARLY TREATMENT DIABETIC RETINOPATHY STUDY CHART; EYE EXAMINATION; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; QUANTITATIVE DIAGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; RETINA MACULA HEMORRHAGE; RETREATMENT; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; VISUAL ACUITY CHART; DEGENERATION; DRUG ANTAGONISM; EXUDATIVE MACULAR DEGENERATION; IMAGING; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETINA MACULA LUTEA; VERY ELDERLY; VISION;

DEGENERATION; IMAGING; MACULA; RETINA; VISION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; RECURRENCE; RETINA; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84908297394     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304399     Document Type: Article

References (26)

1. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002;86:716-22.
2. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17.
3. Algvere PV, Seregard S. Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand 2002;80:136-43.
4. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46.
5. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-72.
6. Gonzales CR. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005;25:815-27.
7. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-56.
8. Cheung CM, Wong TY. Ranibizumab and bevacizumab for AMD. N Engl J Med 2011;365:2237.
9. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.
10. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
11. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897-908.
12. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9.
13. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71.
14. Singer MA, Awh CC, Sadda S, et al. HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Ophthalmology 2012;119:1175-83.
15. Finger RP, Holz FG. [Access to healthcare services for elderly patients with neovascular age-related macular degeneration]. Ophthalmologe 2012;109:474-8.
16. Framme C, Wolf-Schnurrbusch UE, Lobsiger H, et al. [Adapted and standardised patient management in the treatment of neovascular AMD in the outpatient setting of a university eye hospital]. Klin Monbl Augenheilkd 2012;229:812-21.
17. Wolf A, Reznicek L, Muhr J, et al. [Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme.]. Ophthalmologe 2012;8:740-5.
18. Cohen SY, Dubois L, Ayrault S, et al. Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefe's archive for clinical and experimental ophthalmology=Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie 2013;251:2499-503.
19. Colenbrander A, Fletcher DC. Low vision rehabilitation: visual acuity measurement in the low vision range. J Ophthalmic Nurs Technol 1992;11:62-9.
20. Bloch SB, la Cour M, Sander B, et al. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol 2013;91:42-7.
21. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-37.
22. Patel PJ, Tufail A, for the ABCTI. Optimizing Individualized Therapy with Bevacizumab for Neovascular Age-Related Macular Degeneration. Retina Published Online First: 31 Jan 2012. doi:10.1097/IAE.0b013e31823f0ba3.
23. Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefe's archive for clinical and experimental ophthalmology=Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie 2014;252:647-55.
24. Cohen SY, Oubraham H, Uzzan J, et al. Causes of Unsuccessful Ranibizumab Treatment in Exudative Age-Related Macular Degeneration in Clinical Settings. Retina 2012;32:1480-5.
25. Muether PS, Hoerster R, Hermann MM, et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefe's archive for clinical and experimental ophthalmology=Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie 2013;251:453-8.
26. Manousaridis K, Manjunath V, Talks J. Information used to decide on retreatment of exudative age-related macular degeneration with anti-VEGF in clinical practice. Eur J Ophthalmol 2013;23:108-13.